Twist Bioscience Corporation (NASDAQ: TWST), recognized as a mid-cap growth and value biotech firm, has announced a collaboration with Synthetic Design Lab (SDL), a company focused on next-generation therapeutics.

“With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics,” stated Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. She emphasized that Twist is “uniquely positioned to support Synthetic Design Lab’s development of novel antibody-drug conjugates for various cancer types.”

The partnership will allow SDL to utilize Twist's extensive high throughput services to further its mission. “Collaborating with Twist, we’re able to leverage their extensive suite of high throughput services to help us advance on our mission to unlock the full potential of our proprietary approach,” said Daniel S. Chen, M.D., Ph.D., Chief Executive Officer of Synthetic Design Lab. He expressed confidence in their SYNTHBODY platform, stating, “We believe that with our SYNTHBODY platform, we can develop a broad suite of therapeutics that are far more advanced than what is available today.”

Twist is employing its proprietary tools and platform to conduct specific research activities, thereby supporting the initiatives of Synthetic Design Lab.

Twist Biopharma Solutions, the biologics discovery and optimization services group within Twist Bioscience, combines high-throughput DNA synthesis technology with extensive expertise in antibody engineering. This approach provides end-to-end antibody discovery solutions tailored to the specific needs of partners. The ability to manufacture DNA at scale allows Twist to create proprietary antibody libraries, initiating discovery with either in vivo or in vitro diversity. This method offers partners a reliable resource for antibody therapeutic discovery and optimization. The combination of precise library fabrication, sophisticated bioinformatics, and software capabilities accelerates antibody discovery while minimizing risk and increasing speed.

Moreover, in vivo discovery methods, such as single B cell screening and hybridoma discovery, enable multiple technology methods to create a diverse panel of antibody leads. The automated screening and panning processes allow for the identification of high-affinity leads that partners can advance into clinical trials. Twist also provides supporting development capabilities, including IgG conversion, expression, purification, and both biophysical and functional characterization.

For more information about Twist Biopharma Solutions, visit: https://www.twistbioscience.com/twist-biopharma-solutions.

Twist Bioscience Corporation aims to serve customers who are making significant contributions to various fields, including medicine and agriculture, by using synthetic DNA tools to enhance lives and promote sustainability. The company’s innovative silicon-based DNA Synthesis Platform offers unparalleled precision and efficiency. “The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts,” the company noted.

‍

‍